Long Term Returns of ValueAct Capital’s Activist Targets

In This Article:

In this article we're going to discuss the long-term returns of ValueAct Capital's activist targets. If you want to see more stocks from our selection, we suggest you navigate to our picks of Long Term Returns of Value Act Capital's 5 Activist Targets.

ValueAct Capital is a hedge fund that was co-founded in 2000 by Jeff Ubben and over the years it has become one of the most famous activist funds on the Street. Ubben prefers to take a fairly “mild” activist approach towards his investments. Unlike other activists, rather than engaging in proxy fights and promoting drastic measures (like hostile takeovers), Ubben and his team seek board representation and partnerships with big shareholders and top managers to stimulate growth and unlock value. 

As an activist fund, ValueAct has made a name for itself by getting involved in giants like Microsoft Corp (NASDAQ:MSFT), Adobe Inc (NASDAQ:ADBE), and more recently New York Times Co (NYSE:NYT) and Salesforce Inc (NYSE:CRM). The fund scored an average return of over 40% per year since its inception, outperforming the S&P 500 by a wide margin. 

In its latest 13F filing, ValueAct disclosed holding investments in just nine companies and historical data shows that the fund prefers holding a more concentrated portfolio. The fund usually keeps its investments for a period of at least three-to-four years, as it happened with the aforementioned Microsoft Corp (NASDAQ:MSFT), Adobe Inc (NASDAQ:ADBE), and Citigroup Inc (NYSE:C), which made the list of long term returns of ValueAct Capital’s Activist targets. However, it also has more long-term positions like CBRE Group Inc (NYSE:CBRE), Gartner Inc (NYSE:IT), and Bausch Health Companies Inc (NYSE:BHC), which you can find more details about under Long Term Returns of Value Act Capital's 5 Activist Targets.

Even though the portfolio doesn't contain a lot of stocks, it is diversified across sectors. Over the years, ValueAct prefers to switch its focus from one sector to another, but generally, the majority of its holdings are focused in Finance, Technology, and Healthcare. However, in the last several quarters, ValueAct exited the healthcare sector and currently more than half of its $6.5 billion 13F portfolio is in tech stocks.  

Ubben himself is no longer involved in ValueAct, having stepped down in 2020, after handing over the reins of the main fund to Mason Morfit, who is currently the Chief Executive Office and Chief Investment Officer. In 2018, Ubben started managing ValueAct’s ESG-focused (environmental, social, and governance) fund ValueAct Spring Capital, but two years later stepped down to launch a new venture, Inclusive Capital, which is focused on impact investing